NCT05566262进行中（未招募）4 期
An Investigator Initiated Open-label Study Evaluating the Efficacy and Tolerability of Application of Bodewell Products for the Treatment of Atopic Dermatitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Mean Percentage improvement in Patient Global Assessment (PGA)
研究概览
简要总结
This study aims to examine the safety and efficacy of topical application of the Bodewell eczema products
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •In good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, clinical laboratories, and urinalysis. (NOTE: The definition of good health means a subject does not have uncontrolled significant co- morbid conditions).
- •18 years of age or older
- •Able and willing to give written informed consent prior to any study procedures being conducted, and authorize the release and use of protected health information (PHI)
- •Willing to have photos taken of their skin
- •Diagnosis of chronic atopic dermatitis that has been present for at least 6 months prior to baseline
- •Atopic dermatitis involving at least 3-10 % of the patient's body surface area
- •Must have discontinued all systemic therapies for the treatment of atopic dermatitis at least 4 weeks or 5 half-lives, and biologics 6 months prior to baseline visit
- •Must have discontinued all topical therapies for the treatment of atopic dermatitis at least 2 weeks prior to baseline visit
- •Females of childbearing potential must use an approved birth control method while receiving treatment and for 28 days following the investigational product and there must be a documented negative pregnancy tests prior to initiating treatment. Approved birth control methods include hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring), intrauterine device, tubal ligation, partner vasectomy, or male or female condoms that are not made of natural materials PLUS a diaphragm with spermicide, cervical cap with spermicide, or a contraceptive sponge with spermicide.
- •Females not of child bearing potential are defined as being at least 1 year postmenopausal or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy).
- •5 patients must be on a stable dose of systemic therapy for the last 6 months prior to screening visit
- •5 patients must be skin of color
排除标准
- •Other than disease under study, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled
- •Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study
- •Prior history of suicide attempt at any time in the subject's life time prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years
- •Pregnant or breast feeding
- •Active substance abuse or a history of substance abuse within 6 months prior to Screening
- •Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer)
- •Prior treatment with the investigational product within 4 weeks prior to randomization
- •Unable to comply with the protocol (as defined by the Investigator; i.e. drug or alcohol abuse or history of noncompliance)
- •Any other dermatologic conditions that prohibit or confound the ability of the investigator to interpret skin findings.
- •Patients who will be unable to avoid the use of systemic steroids, excluding intranasal or inhaled steroids that will be permitted, for the duration of the trial
研究组 & 干预措施
Bodewell Treatment
Experimental
All patients will be treated with the active product, Bodewell. Bodewell will be applied topically twice a day to all active lesions.
干预措施: Bodewell Calming Cream (Drug)
结局指标
主要结局
Mean Percentage improvement in Patient Global Assessment (PGA)
时间窗: Baseline to week 12
Mean percentage improvement in the Patient Global Assessment from baseline to week 12. This assessment is a scale from 0 to 4. 0 means clear skin while 4 means severe disease.
次要结局
- Percent improvement in Dermatology Life Quality Index (DLQI)(Baseline to week 12)
研究者
Tiffany Mayo, MD
Assistant Professor
University of Alabama at Birmingham
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell CarcinomaCarcinoma, Basal CellNCT00204555University Hospital Tuebingen100
终止
2 期
Safety and Efficacy of P-188 NF in DMD PatientsDuchenne Muscular DystrophyNCT03558958Phrixus Pharmaceuticals, Inc.2
已完成
1 期
Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control GelAcne VulgarisNCT03653403Bausch Health Americas, Inc.61
已完成
早期 1 期
Open-Label Pilot Study of the Efficacy and Safety of Vusion Ointment for the Treatment of IntertrigoIntertrigoNCT01118910Image Dermatology P.C.15
已完成
不适用
Evaluate the Ability of dOFM for BE Testing of Topically Applied Diclofenac Sodium Products in Healthy SubjectsHealthyNCT04592016Joanneum Research Forschungsgesellschaft mbH22